Signaturefd LLC Acquires 240 Shares of Amgen Inc. (NASDAQ:AMGN)

Signaturefd LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 14,486 shares of the medical research company’s stock after acquiring an additional 240 shares during the period. Signaturefd LLC’s holdings in Amgen were worth $4,668,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Sequoia Financial Advisors LLC raised its position in shares of Amgen by 9.5% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 134,582 shares of the medical research company’s stock valued at $43,364,000 after acquiring an additional 11,679 shares during the last quarter. Home Federal Bank of Tennessee raised its position in shares of Amgen by 4.0% during the 3rd quarter. Home Federal Bank of Tennessee now owns 2,598 shares of the medical research company’s stock valued at $837,000 after acquiring an additional 101 shares during the last quarter. DeDora Capital Inc. raised its position in shares of Amgen by 1.4% during the 3rd quarter. DeDora Capital Inc. now owns 5,436 shares of the medical research company’s stock valued at $1,752,000 after acquiring an additional 76 shares during the last quarter. Calton & Associates Inc. increased its position in shares of Amgen by 18.7% in the 3rd quarter. Calton & Associates Inc. now owns 844 shares of the medical research company’s stock valued at $272,000 after buying an additional 133 shares in the last quarter. Finally, Oakworth Capital Inc. increased its position in shares of Amgen by 23.2% in the 3rd quarter. Oakworth Capital Inc. now owns 1,505 shares of the medical research company’s stock valued at $485,000 after buying an additional 283 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Argus upped their price objective on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and upped their price objective for the company from $320.00 to $333.00 in a research report on Monday, October 14th. Oppenheimer restated an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a research report on Wednesday, August 7th. Finally, TD Cowen upped their target price on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Amgen has an average rating of “Moderate Buy” and a consensus target price of $332.55.

Amgen Stock Performance

NASDAQ:AMGN traded up $0.18 during mid-day trading on Tuesday, hitting $316.92. The stock had a trading volume of 448,320 shares, compared to its average volume of 2,433,690. Amgen Inc. has a twelve month low of $249.70 and a twelve month high of $346.85. The stock has a market cap of $170.01 billion, a price-to-earnings ratio of 45.06, a PEG ratio of 2.86 and a beta of 0.61. The company’s 50 day simple moving average is $326.00 and its 200 day simple moving average is $312.76. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The company had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm’s revenue was up 20.1% compared to the same quarter last year. During the same period in the prior year, the company earned $5.00 earnings per share. On average, equities research analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.84%. Amgen’s dividend payout ratio is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.